Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 7(1): 157, 2017 03 13.
Article in English | MEDLINE | ID: mdl-28279017

ABSTRACT

Herbicides have long-term effects on the vegetative parts and reproduction of plants; however, the carry-over effects of herbicides on the F1 generation of invasive plants remain unclear. The objectives of this work were to investigate the germination and growth of the F1 generation of A. retroflexus, an invasion plant, treated by sublethal herbicides. The results demonstrated that atrazine or tribenuron-methyl had carry-over effects on the F1 generation of A. retroflexus. Atrazine or tribenuron-methyl exposure during the vegetative and reproductive periods significantly inhibited the germination and growth of the F1 generation; a lower sublethal dose of atrazine or tribenuron-methyl did not weaken the inhibition of germination or growth of the F1 generation. Our results suggest that although herbicides have a carry-over inhibition effect on the F1 generation of invasive plants, they may have a more serious carry-over effect on native plants and cause changes in weed species composition and weed diversity.


Subject(s)
Amaranthus/physiology , Germination/drug effects , Herbicides/adverse effects , Seedlings/growth & development , Amaranthus/drug effects , Arylsulfonates/adverse effects , Atrazine/adverse effects , Introduced Species , Seedlings/drug effects
2.
J Am Assoc Nurse Pract ; 29(2): 104-115, 2017 Feb.
Article in English | MEDLINE | ID: mdl-28139897

ABSTRACT

PURPOSE: We review the use of oral antiplatelet (OAP) therapies in acute coronary syndrome (ACS) management for nurse practitioners (NPs), focusing on current guideline recommendations. DATA SOURCES: Treatment guidelines and clinical articles from PubMed. CONCLUSIONS: Guidelines recommend that dual antiplatelet therapy with a P2Y12 inhibitor and aspirin be initiated for ACS management. The P2Y12 inhibitor clopidogrel has established efficacy, but is associated with suboptimal and delayed platelet inhibition and variability in response. The newer P2Y12 inhibitors prasugrel and ticagrelor have demonstrated superior efficacy outcomes versus clopidogrel. Consequently, non-ST-segment elevation ACS (NSTE-ACS) guidelines now recommend that ticagrelor be used in preference to clopidogrel for patients treated with stents or managed medically. Because of their higher potency, prasugrel and ticagrelor are associated with increased bleeding rates versus clopidogrel, but with no increased risk of severe or life-threatening bleeding. Guidelines recommend dual antiplatelet therapy be continued ≥12 months in both medically managed and stented ACS patients, and in some cases beyond this, in absence of high bleeding risk. Updated guidelines assign preference to ticagrelor over clopidogrel for maintenance therapy in patients with NSTE-ACS and ST-elevation myocardial infarction. IMPLICATIONS FOR PRACTICE: Enhanced NP understanding of OAP agents and current guidelines could contribute to improved ACS patient management.


Subject(s)
Acute Coronary Syndrome/drug therapy , Administration, Oral , Disease Management , Platelet Aggregation Inhibitors/therapeutic use , Adenosine/adverse effects , Adenosine/analogs & derivatives , Adenosine/therapeutic use , Arylsulfonates/adverse effects , Arylsulfonates/therapeutic use , Aspirin/adverse effects , Aspirin/therapeutic use , Clopidogrel , Humans , Nurse Practitioners , Platelet Aggregation Inhibitors/adverse effects , Prasugrel Hydrochloride/adverse effects , Prasugrel Hydrochloride/therapeutic use , Ticagrelor , Ticlopidine/adverse effects , Ticlopidine/analogs & derivatives , Ticlopidine/therapeutic use
3.
Asian Pac J Allergy Immunol ; 29(2): 134-42, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21980828

ABSTRACT

BACKGROUND AND OBJECTIVE: Suplatast tosilate is a Th2 cytokine inhibitor that is effective for controlling persistent asthma. However, the long-term efficacy of suplatast is unknown. We compared the clinical efficacy of long-term monotherapy with suplatast tosilate with a low dose of inhaled steroids in patients with mild atopic asthma. METHODS: A total of 32 patients with mild atopic asthma were randomly assigned to receive suplatast (n=15) or fluticasone (n=17). In the suplatast group, 100 mg of suplatast was given orally 3 times a day (total daily dose = 300 mg) for 2 years. In the fluticasone group, 100 pg of fluticasone was inhaled twice a day (total daily dose = 200 tg) for 2 years. RESULTS: In the suplatast group, the improvements in peak expiratory flow (PEF) rate and forced expiratory volume in 1 second (FEV1) and the changes in the symptom diary scale and frequency of beta2 stimulant inhalation were generally similar to those in the fluticasone group, and efficacy was maintained for 2 years. Improvements in inflammatory indices, such as the sputum eosinophil cationic protein (ECP) level and exhaled nitric oxide concentration, were comparable in the suplatast and fluticasone groups. The improvement in airway hyperresponsiveness was also similar in the 2 groups. The peripheral blood eosinophil percent change, serum ECP level, and total IgE antibody titer improved only in the suplatast group. CONCLUSIONS: Long-term treatment with suplatast significantly improved symptoms and inflammatory indices in patients with mild atopic asthma. Along with fluticasone, suplatast is considered a useful drug for the management of mild atopic asthma.


Subject(s)
Androstadienes/administration & dosage , Arylsulfonates/administration & dosage , Asthma/drug therapy , Sulfonium Compounds/administration & dosage , Administration, Inhalation , Adult , Aged , Aged, 80 and over , Androstadienes/adverse effects , Arylsulfonates/adverse effects , Asthma/diagnosis , Asthma/physiopathology , Disease Progression , Drug Dosage Calculations , Female , Fluticasone , Follow-Up Studies , Humans , Male , Middle Aged , Pilot Projects , Respiratory Function Tests , Sulfonium Compounds/adverse effects , Treatment Outcome
4.
J Asthma ; 42(7): 567-70, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16169790

ABSTRACT

Suplatast tosilate is an antiallergic drug that selectively suppresses Th2-cytokine production and inhibits airway hyperresponsiveness and eosinophilic airway inflammation. This drug has been also shown to improve pulmonary function and symptoms in steroid-dependent asthma, resulting in a decrease in doses of inhaled corticosteroid. However, the precise mechanism by which suplatast tosilate exerts an antiasthmatic effect in vivo remains to be known. Our previous study showed the polarization of circulating type 1 dendritic cells (DC1)/type 2 dendritic cells (DC2) balance toward DC2 in asthma, which might be associated with its Th2-dominant immune response. In the present study, we attempted to clarify the effect of suplatast tosilate on DC1/DC2 balance in asthma. Using multicolor flow cytometry, we enumerated circulating DC1 and DC2 before and 8 weeks after treatment with suplatast tosilate in nine patients with asthma. Before the treatment, the patients with asthma had a significant higher percentage of DC2 together with a significant lower ratio of DC1/DC2 compared with normal subjects. Administration of suplatast tosilate significantly decreased the percentage of DC2, but not that of DC1, resulting in a significant raises of the ratio of DC1/DC2. Concomitantly, intracellular cytokine analysis showed that the percentage of IL-4 producing CD4+ T cells was significantly decreased after the treatment. These data suggest that suplatast tosilate normalizes the polarized DC1/DC2 balance toward DC2 in asthma, which may also alter its Th2-dominant Th1/Th2 balance toward Th1.


Subject(s)
Anti-Allergic Agents/therapeutic use , Antigen-Presenting Cells/drug effects , Arylsulfonates/therapeutic use , Asthma/drug therapy , Dendritic Cells/drug effects , Histamine Antagonists/therapeutic use , Sulfonium Compounds/therapeutic use , Adrenal Cortex Hormones/administration & dosage , Aged , Anti-Allergic Agents/adverse effects , Arylsulfonates/adverse effects , Asthma/immunology , Blood Cell Count , Bronchial Hyperreactivity/blood , Bronchial Hyperreactivity/drug therapy , Dendritic Cells/classification , Dendritic Cells/immunology , Dose-Response Relationship, Drug , Drug Therapy, Combination , Female , Forced Expiratory Volume/drug effects , Health Services Accessibility/statistics & numerical data , Histamine Antagonists/adverse effects , Humans , Male , Middle Aged , Sulfonium Compounds/adverse effects , Treatment Outcome
5.
Oral Dis ; 9(5): 273-6, 2003 Sep.
Article in English | MEDLINE | ID: mdl-14628896

ABSTRACT

OBJECTIVE: The purpose of this report is to document the presence of dimethyl sulfide in mouth air as the predominant volatile sulfur compound (VSC) in an asthmatic patient who was regularly taking suplatast tosilate. STUDY DESIGN: The patient was a 33-year-old woman who complained of bad breath. She had been diagnosed as having asthma and was receiving periodical medical examinations once a month. VSC in her mouth air were measured with a gas chromatograph. Oral physiotherapy was also carried out to remove any oral malodor of which the source was intraoral. RESULTS: With the improvement in oral hygiene and periodontal conditions, the level of VSC was reduced but dimethyl sulfide still remained as the predominant VSC. CONCLUSIONS: Dimethyl sulfide metabolized from suplatast tosilate may be a potential cause of halitosis.


Subject(s)
Anti-Asthmatic Agents/adverse effects , Halitosis/chemically induced , Adult , Arylsulfonates/adverse effects , Asthma/drug therapy , Chromatography, Gas , Female , Halitosis/metabolism , Humans , Sulfides/analysis , Sulfonium Compounds/adverse effects
6.
J Environ Biol ; 23(4): 353-8, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12674373

ABSTRACT

The presence of chlorimuron ethyl and metsulfuron methyl in two soils was determined by a modified petri dish bioassay. Pregerminated seeds of maize and sunflower were placed in petri dishes containing 85 to 100 g of treated soil. Radicle root lengths were measured after 24 h. Chlorimuron had no effect on maize on the Balcarce soil, however 0.007 microg g(-1) decreased sunflower root length. Chlorimuron decreased maize and sunflower root length regardless application dose on the San Cayetano soil. Metsulfuron decreased maize root length at 0.04 microg g(-1) and sunflower at 0.021 microg g(-1) on the Balcarce soil. On the San Cayetano soil metsulfuron at 0.001 microg g(-1) decreased maize and sunflower root length. The phytotoxicity of chlorimuron and metsulfuron changed according to soil type and dose. Maize and sunflower were 1.3-1.5 and 1.3-1.8 times respectively more sensitive to chlorimuron on the San Cayetano soil than on the Balcarce soil. In the case of metsulfuron, maize was similarly sensitive on both soils but sunflower was 1.7-2.0 times more sensitive on the San Cayetano soil than on the Balcarce soil. Phytotoxicity increased as organic matter (OM) content decreased and/or when the soil pH and concentration increased.


Subject(s)
Arylsulfonates/analysis , Pesticide Residues/analysis , Pyrimidines/analysis , Soil Pollutants/analysis , Sulfonylurea Compounds/analysis , Argentina , Arylsulfonates/adverse effects , Biological Assay/methods , Helianthus/growth & development , Pesticide Residues/adverse effects , Pyrimidines/adverse effects , Seeds/growth & development , Soil Pollutants/adverse effects , Sulfonylurea Compounds/adverse effects , Zea mays/growth & development
SELECTION OF CITATIONS
SEARCH DETAIL
...